VX-745 |
VX-745 : ATP competitive inhibitor of MAPK14
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| MAPK14 |
|
ATP competitive
50-100 nM
Selectivity
In Vitro Selectivity Assessment
Potency: KD - MAPK11 74 nM
Potency Assay Off-Target:
VX-745 was 20-fold selective for MAPK14 (p38alpha) > MAPK11 (p38beta) in IC50 assays.
VX-745 was te ...
Potency Cellular
In Vitro
MAPK14
Mode of Action: ATP competitive
Structure-Activity-Relationship data available? No
In Vivo Validations
BALB/c mice (Sprague-Dawley rats)
Dose: 40 mg/kg (43 mg/kg)
Route of delivery:
Oral
Plasma half life:
4.5 h (both species)
Reference: --
Chemical Information
| Molecular Formula | C19H9Cl2F2N3OS |
| SMILEs | O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl |
| InChI | InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H |
| Molecular weight | 434.98 Da |
| AlogP | 5.492700000000003 |
| HBond acceptors | 4 |
| HBond donors | -- |
| Atoms | 37 |
References
Publications
Cross References
Vendors
- Cayman (209410-46-8)
- MedChem Express (209410-46-8)
- MilliporeSigma (209410-46-8)
- Tocris (209410-46-8)
Note: This is not an exhaustive list and does not indicate endorsement by the portal.